{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T16:10:05Z","timestamp":1788711005937,"version":"build-2803163510"},"reference-count":47,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"unspecified","delay-in-days":68,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2025,11,23]]},"published-print":{"date-parts":[[2026,1]]},"abstract":"\n Objective<\/jats:title>\n To present updated integrated safety analyses of bimekizumab in patients with axial spondyloarthritis (axSpA) or psoriatic arthritis (PsA).<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Safety data pooled from six phase IIb\/III studies in axSpA and PsA (data-cut: July 2023 for phase III) reported for patients who received \u22651\u2009dose of bimekizumab 160\u2009mg every 4 weeks. Treatment-emergent adverse events (TEAEs) were reported using exposure-adjusted incidence rate per 100 patient-years (EAIR\/100 PY).<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n 848 patients with axSpA (total exposure: 2513.8 PY) and 1409 patients with PsA (3655.9 PY) were included. TEAE incidence (EAIR\/100 PY) was 129.6 in axSpA and 126.9 in PsA. Study discontinuations due to TEAEs were infrequent (EAIR\/100 PY for axSpA: 2.4; PsA: 2.9). The most frequent TEAEs were SARS-CoV-2 (COVID-19) infection (EAIR\/100 PY for axSpA: 9.9; PsA: 9.9), nasopharyngitis (EAIR\/100 PY for axSpA: 8.4; PsA: 6.8) and upper respiratory tract infection (EAIR\/100 PY for axSpA: 5.0; PsA: 5.7). EAIR\/100 PY for oral candidiasis was 3.5 in axSpA and 3.8 in PsA; most cases were mild\/moderate, with few leading to study discontinuation (EAIR\/100 PY for axSpA: 0.2; PsA: 0.3). Serious opportunistic infections were infrequent (EAIR\/100 PY for axSpA: 0; PsA: 0.1), with no active tuberculosis. EAIR\/100 PY for hepatic events was 5.3 in axSpA and 5.0 in PsA. EAIRs for adjudicated definite\/probable inflammatory bowel disease, uveitis, adjudicated major adverse cardiovascular events and adjudicated suicidal ideation\/behaviour were low.<\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n TEAE EAIRs were similar between axSpA and PsA. Bimekizumab demonstrated tolerability up to 5 years (2 years in phase III); no new safety signals were identified.<\/jats:p>\n <\/jats:sec>\n \n Trial registration numbers<\/jats:title>\n \n NCT02963506<\/jats:ext-link>\n ;\n NCT03355573<\/jats:ext-link>\n ;\n NCT03928704<\/jats:ext-link>\n ;\n NCT03928743<\/jats:ext-link>\n ;\n NCT04436640<\/jats:ext-link>\n ;\n NCT02969525<\/jats:ext-link>\n ;\n NCT03347110<\/jats:ext-link>\n ;\n NCT03895203<\/jats:ext-link>\n ;\n NCT03896581<\/jats:ext-link>\n ;\n NCT04009499<\/jats:ext-link>\n .\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1136\/rmdopen-2025-006174","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T16:56:02Z","timestamp":1773161762000},"page":"e006174","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Bimekizumab longer-term safety profile in adult patients with axial spondyloarthritis or psoriatic arthritis: an updated analysis of six phase IIb\/III clinical studies"],"prefix":"10.1136","volume":"12","clinical-trial-number":[{"clinical-trial-number":"nct02963506","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03355573","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03928704","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03928743","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04436640","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02969525","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03347110","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03895203","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03896581","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02963506","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03928704","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02963506","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03928704","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03928743","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02969525","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03895203","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03896581","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03355573","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04436640","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03347110","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04009499","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02963506","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03355573","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03928704","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03928743","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04436640","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02969525","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03347110","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03895203","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03896581","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04009499","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6620-0457","authenticated-orcid":false,"given":"Philip J","family":"Mease","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Providence-Swedish Medical Center, Seattle, Washington, USA"},{"name":"University of Washington, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph F","family":"Merola","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Department of Medicine, Division of Rheumatology, UT Southwestern Medical Center, Dallas, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Magrey","sequence":"additional","affiliation":[{"name":"Case Western Reserve University, University Hospitals, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2571-788X","authenticated-orcid":false,"given":"Peter","family":"Nash","sequence":"additional","affiliation":[{"name":"School of Medicine, Griffith University, Brisbane, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Poddubnyy","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, University of Toronto and University Health Network, Toronto, Ontario, Canada"},{"name":"Department of Gastroenterology, Infectious Diseases and Rheumatology, Charit\u00e9\u2013 Universit\u00e4tsmedizin Berlin, Berlin, Germany"},{"name":"Department of Epidemiology, German Rheumatism Research Centre, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Lebwohl","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajan","family":"Bajracharya","sequence":"additional","affiliation":[{"name":"UCB, Slough, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Ink","sequence":"additional","affiliation":[{"name":"UCB, Slough, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Marten","sequence":"additional","affiliation":[{"name":"UCB, Monheim am Rhein, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Manente","sequence":"additional","affiliation":[{"name":"UCB, Braine-l\u2019Alleud, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Peterson","sequence":"additional","affiliation":[{"name":"UCB, Morrisville, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katy","family":"White","sequence":"additional","affiliation":[{"name":"UCB, Slough, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianne S","family":"Gensler","sequence":"additional","affiliation":[{"name":"Department of Medicine\/Rheumatology, University of California, San Francisco, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,3,10]]},"reference":[{"key":"2026090304051152000_12.1.e006174.1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221035"},{"key":"2026090304051152000_12.1.e006174.2","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1016\/S0140-6736(18)30830-4","article-title":"The pathogenesis of psoriatic arthritis","volume":"391","author":"Veale","year":"2018","journal-title":"The Lancet"},{"key":"2026090304051152000_12.1.e006174.3","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003063","article-title":"Axial spondyloarthritis and psoriatic arthritis: mostly overlapping or substantially different diseases?","volume":"9","author":"Braun","year":"2023","journal-title":"RMD Open"},{"key":"2026090304051152000_12.1.e006174.4","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-019-00172-9"},{"key":"2026090304051152000_12.1.e006174.5","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2018.1468252"},{"key":"2026090304051152000_12.1.e006174.6","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000000589"},{"key":"2026090304051152000_12.1.e006174.7","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001306","article-title":"Dual neutralisation of IL-17F and IL-17A with bimekizumab blocks inflammation-driven osteogenic differentiation of human periosteal cells","volume":"6","author":"Shah","year":"2020","journal-title":"RMD Open"},{"key":"2026090304051152000_12.1.e006174.8","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212127"},{"key":"2026090304051152000_12.1.e006174.9","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-018-8702-3"},{"key":"2026090304051152000_12.1.e006174.10","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/bjd\/ljad345","article-title":"Hidradenitis suppurativa: new insights into disease mechanisms and an evolving treatment landscape","volume":"190","author":"Krueger","year":"2024","journal-title":"Br J Dermatol"},{"key":"2026090304051152000_12.1.e006174.11","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-225240"},{"key":"2026090304051152000_12.1.e006174.12","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0140-6736(22)02302-9","article-title":"Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL)","volume":"401","author":"McInnes","year":"2023","journal-title":"The Lancet"},{"key":"2026090304051152000_12.1.e006174.13","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0140-6736(22)02303-0","article-title":"Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-\u03b1 inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)","volume":"401","author":"Merola","year":"2023","journal-title":"The Lancet"},{"key":"2026090304051152000_12.1.e006174.14","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1016\/S0140-6736(24)00101-6","article-title":"Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials","volume":"403","author":"Kimball","year":"2024","journal-title":"The Lancet"},{"key":"2026090304051152000_12.1.e006174.15","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0140-6736(21)00126-4","article-title":"Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial","volume":"397","author":"Gordon","year":"2021","journal-title":"The Lancet"},{"key":"2026090304051152000_12.1.e006174.16","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0140-6736(21)00125-2","article-title":"Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial","volume":"397","author":"Reich","year":"2021","journal-title":"The Lancet"},{"key":"2026090304051152000_12.1.e006174.17","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2102383"},{"key":"2026090304051152000_12.1.e006174.18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2102388"},{"key":"2026090304051152000_12.1.e006174.19","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1093\/rheumatology\/keaf009","article-title":"Long-term safety and efficacy of bimekizumab in axial spondyloarthritis: 2-year results from two phase 3 studies","volume":"64","author":"Baraliakos","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"2026090304051152000_12.1.e006174.20","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-005081","article-title":"Long-term safety and sustained efficacy of bimekizumab in patients with ankylosing spondylitis (radiographic axial spondyloarthritis): 5-year results from BE AGILE (phase 2b) and its open-label extension","volume":"11","author":"Deodhar","year":"2025","journal-title":"RMD Open"},{"key":"2026090304051152000_12.1.e006174.21","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1007\/s40744-024-00708-8","article-title":"Safety and efficacy of bimekizumab in patients with psoriatic arthritis: 2-year results from two phase 3 studies","volume":"11","author":"Mease","year":"2024","journal-title":"Rheumatol Ther"},{"key":"2026090304051152000_12.1.e006174.22","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1002\/art.42280","article-title":"Safety and efficacy of bimekizumab in patients with active psoriatic arthritis: three-year results from a phase IIb randomized controlled trial and its open-label extension study","volume":"74","author":"Coates","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"2026090304051152000_12.1.e006174.23","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1001\/jamadermatol.2022.1185","article-title":"Bimekizumab safety in patients with moderate to severe plaque psoriasis: pooled results from phase 2 and phase 3 randomized clinical trials","volume":"158","author":"Gordon","year":"2022","journal-title":"JAMA Dermatol"},{"key":"2026090304051152000_12.1.e006174.24","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1001\/jamadermatol.2021.2905","article-title":"Efficacy and safety of bimekizumab in moderate to severe hidradenitis suppurativa: a phase 2, double-blind, placebo-controlled randomized clinical trial","volume":"157","author":"Glatt","year":"2021","journal-title":"JAMA Dermatol"},{"key":"2026090304051152000_12.1.e006174.25","doi-asserted-by":"crossref","DOI":"10.3390\/jof3040052","article-title":"The role of IL-17 in protection against mucosal candida infections","volume":"3","author":"Mengesha","year":"2017","journal-title":"J Fungi (Basel)"},{"key":"2026090304051152000_12.1.e006174.26","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-022-00746-9"},{"key":"2026090304051152000_12.1.e006174.27","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1093\/rheumatology\/kead705","article-title":"Comparative efficacy and safety of bimekizumab in psoriatic arthritis: a systematic literature review and network meta-analysis","volume":"63","author":"Mease","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"2026090304051152000_12.1.e006174.28","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1093\/rheumatology\/kead598","article-title":"Comparative efficacy and safety of bimekizumab in axial spondyloarthritis: a systematic literature review and network meta-analysis","volume":"63","author":"Deodhar","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"2026090304051152000_12.1.e006174.29","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-005026","article-title":"Long-term safety of bimekizumab in adult patients with axial spondyloarthritis or psoriatic arthritis: pooled results from integrated phase IIb\/III clinical studies","volume":"11","author":"Mease","year":"2025","journal-title":"RMD Open"},{"key":"2026090304051152000_12.1.e006174.30","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223595"},{"key":"2026090304051152000_12.1.e006174.31","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-216980"},{"key":"2026090304051152000_12.1.e006174.32","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0140-6736(19)33161-7","article-title":"Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial","volume":"395","author":"Ritchlin","year":"2020","journal-title":"The Lancet"},{"key":"2026090304051152000_12.1.e006174.33","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/j.jpsychires.2010.04.025","article-title":"Feasibility and validation of a computer-automated Columbia-Suicide Severity Rating Scale using interactive voice response technology","volume":"44","author":"Mundt","year":"2010","journal-title":"J Psychiatr Res"},{"key":"2026090304051152000_12.1.e006174.34","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2011.10111704"},{"key":"2026090304051152000_12.1.e006174.35","doi-asserted-by":"publisher","DOI":"10.1046\/j.1525-1497.2001.016009606.x"},{"key":"2026090304051152000_12.1.e006174.36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.993057"},{"key":"2026090304051152000_12.1.e006174.37","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1080\/09286586.2020.1856385","article-title":"The impact of adult uveitis on quality of life: an exploratory study","volume":"28","author":"Prem Senthil","year":"2021","journal-title":"Ophthalmic Epidemiol"},{"key":"2026090304051152000_12.1.e006174.38","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-225531"},{"key":"2026090304051152000_12.1.e006174.39","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1136\/ard-2024-225933","article-title":"Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: pooled results from phase 2b\/3 trials","volume":"83","author":"Brown","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2026090304051152000_12.1.e006174.40","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223296"},{"key":"2026090304051152000_12.1.e006174.41","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-023-03257-7","article-title":"Long-term safety of Ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: a post-hoc analysis of final safety data from 25 randomized clinical trials","volume":"26","author":"Deodhar","year":"2024","journal-title":"Arthritis Res Ther"},{"key":"2026090304051152000_12.1.e006174.42","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214273"},{"key":"2026090304051152000_12.1.e006174.43","doi-asserted-by":"crossref","first-page":"8","DOI":"10.5152\/eurjrheum.2021.21022","article-title":"Anxiety and depression among patients with axial spondyloarthritis","volume":"9","author":"Reddy","year":"2021","journal-title":"EJR"},{"key":"2026090304051152000_12.1.e006174.44","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s10067-019-04734-8","article-title":"Systematic review of mental health comorbidities in psoriatic arthritis","volume":"39","author":"Zhao","year":"2020","journal-title":"Clin Rheumatol"},{"key":"2026090304051152000_12.1.e006174.45","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jaad.2024.02.039","article-title":"Mental health outcomes in patients with moderate to severe psoriasis treated with bimekizumab: Analysis of phase 2\/3 randomized trials","volume":"91","author":"Blauvelt","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"2026090304051152000_12.1.e006174.46","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.semarthrit.2015.05.003","article-title":"Risk of liver injury among methotrexate users: A meta-analysis of randomised controlled trials","volume":"45","author":"Conway","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"2026090304051152000_12.1.e006174.47","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00296-016-3487-2","article-title":"Updates on cardiovascular comorbidities associated with psoriatic diseases: epidemiology and mechanisms","volume":"37","author":"Yim","year":"2017","journal-title":"Rheumatol Int"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2025-006174","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T15:56:29Z","timestamp":1788710189000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2025-006174"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,3,10]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1136\/rmdopen-2025-006174"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2025-006174","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]}}}